Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Methotrexate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,059 result(s) found for: Methotrexate. Displaying page 9 of 53.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2009-013072-52 Sponsor Protocol Number: M04-717 Start Date*: 2011-05-09
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicentre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed) Outside EU/EEA NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000352-29 Sponsor Protocol Number: B5381002 Start Date*: 2014-10-27
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ...
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) LT (Completed) HU (Completed) GB (Completed) DE (Completed) ES (Completed) FR (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005330-20 Sponsor Protocol Number: WA20495 Start Date*: 2007-06-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an in...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Temporarily Halted) CZ (Completed) NL (Completed) SI (Completed) SE (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-005353-30 Sponsor Protocol Number: WA20497 Start Date*: 2007-11-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio internacional, randomizado, doble ciego, con grupos de tratamiento paralelos para evaluar la seguridad y eficacia de ocrelizumab en combinación con metotrexato (MTX) comparado con MTX como ...
    Medical condition: Artritis Reumatoide
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) LT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020924-22 Sponsor Protocol Number: RG_09-072 Start Date*: 2011-12-02
    Sponsor Name:University of Birmingham
    Full Title: United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011
    Medical condition: Acute lymphoblastic leukaemia and lymphoblastic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    18.1 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006652-19 Sponsor Protocol Number: NILG-ALL 10/07 Start Date*: 2008-02-06
    Sponsor Name:NILG
    Full Title: A Randomized Pilot Study on Central Nervous System (CNS) Prophylaxis with Liposome-Encapsulated Cytarabine (DepoCyte) in a Population of Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treat...
    Medical condition: 2. Diagnosis of untreated ALL with B-/T-precursor phenotype or B/T-LL, either de novo or secondary to chemo-radiotherapy for other cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005467-29 Sponsor Protocol Number: EMPIRE Start Date*: 2006-03-28
    Sponsor Name:University of Leeds
    Full Title: A multi-centre randomised trial of Etanercept and Methotrexate to induce remission in early inflammatory arthritis resistent to corticosteroid challenge: The EMPIRE trial
    Medical condition: Early arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-007035-27 Sponsor Protocol Number: P061005 Start Date*: 2007-09-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude du rapport urinaire des isomères I et III de la coproporphyrine : Relation avec les retards d'élimination du méthotrexate administré à haute dose chez des patients atteints d'une hémopathie l...
    Medical condition: Patients atteints de LMNH ou de LAL, traités par méthotrexate à dose > 1g/m2.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10031593 LMNH ou LAL PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001428-38 Sponsor Protocol Number: RRK2939 Start Date*: 2006-09-18
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy
    Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001106-26 Sponsor Protocol Number: EC11-444-OSTEOSARC Start Date*: 2012-07-02
    Sponsor Name:JAVIER MARTÍN BROTO
    Full Title: PHASE II MULTICENTRIC AND PROSPECTIVE TRIAL WITH GEMCITABINE AND RAPAMYCIN IN SECOND LINE OF METASTATIC OSTEOSARCOMA
    Medical condition: Patients diagnosed with metastatic osteosarcoma cancer types that have been treated with chemotherapy and have active disease that permits to receive this treatment combination.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005013-37 Sponsor Protocol Number: IDEA v1 Start Date*: 2006-04-06
    Sponsor Name:University of Leeds
    Full Title: A multi-centre randomised double dummy double blind study comparing two regimens of combination induction therapy in early DMARD naive Rheumatoid Arthritis: The IDEA study (Infliximab as Induction ...
    Medical condition: Early Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018279-99 Sponsor Protocol Number: HUM07-066 Start Date*: 2010-05-05
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University Magdeburg
    Full Title: Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis
    Medical condition: Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022795-31 Sponsor Protocol Number: TE 2010-12 Start Date*: 2012-02-20
    Sponsor Name:Barts and the London NHS Trust
    Full Title: A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours with Poor Prognosis
    Medical condition: Relapsed Germ Cell Tumour with poor prognosis
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006665-38 Sponsor Protocol Number: RBM-001-RA002 Start Date*: 2022-11-29
    Sponsor Name:Cyxone AB
    Full Title: APPRAIS - A 24-week multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety and tolerability of orally administered Rabeximod in patients w...
    Medical condition: Active, moderate to severe rheumatoid arthritis with inadequate response to methotrexate
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001659-36 Sponsor Protocol Number: 2011-001659-36 Start Date*: 2011-06-30
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: ABCB1/P-glycoprotein as biological marker for treatment of patient with high grade osteosarcoma
    Medical condition: Non metastatic osteosarcoma of the extremities
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031293 Osteosarcoma localised PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016846-16 Sponsor Protocol Number: OCTO-16 Start Date*: 2010-12-14
    Sponsor Name:University of Oxford
    Full Title: Phase II Clinical Trial of 6-Mercaptopurine(6MP)and low-dose Methotrexate In Patients With Known BRCA Defective Tumours.
    Medical condition: Advanced or metastatic breast or ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028985 Neoplasm breast LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003592-21 Sponsor Protocol Number: CAIN457AGB02 Start Date*: 2016-11-22
    Sponsor Name:Novartis Pharmaceuticals UK Limited
    Full Title: Evaluation of the eFfect of early Initiation of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis Requiring Systemic Treatment (FIRST)
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003493-27 Sponsor Protocol Number: CQAL964B2201 Start Date*: 2014-04-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable dos...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001626-15 Sponsor Protocol Number: ML27828 Start Date*: Information not available in EudraCT
    Sponsor Name:Roche Farma, S.A.
    Full Title: A multi-centre, randomized, double-blind study of the safety and efficacy of tocilizumab (TCZ) in combination with methotrexate (MTX), versus TCZ (placebo controlled) in patients with active rheuma...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-021172-28 Sponsor Protocol Number: NP22523 Start Date*: 2010-10-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Farmacocinética y seguridad de valganciclovir en pacientes pediátricos < 4 meses de edad, receptores de trasplante cardíaco. Pharmacokinetics and safety of valganciclovir in pediatric heart transpl...
    Medical condition: Prevención de la enfermedad por CMV en receptores de trasplantes de órganos sólidos Prevention of CMV disease in solid organ transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009701 CMV LLT
    12.1 10049107 CMV viraemia LLT
    12.1 10060577 CMV viremia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 26 05:00:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA